Accueil・Liste d'Actions・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fermé

SecteurSoins de santé

25.14 1.37

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

24.72

Max

25.07

Chiffres clés
By Trading Economics
Revenu	26M 15M
Ventes	24M 130M
P/E Moyenne du Secteur	112.636 57.366
BPA	0.11
Marge bénéficiaire	11.558
Employés	354
EBITDA	23M 17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+47.58% upside

Dividendes
By Acuity
Prochains Résultats	27 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-130M 3.1B
Ouverture précédente	23.77
Clôture précédente	25.14

Sentiment de l'Actualité

By Acuity

50%

167 / 340 Classement par Healthcare

Arcutis Biotherapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 19:36 UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24 août 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21 août 2026, 19:56 UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20 août 2026, 19:51 UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19 août 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18 août 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14 août 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13 août 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12 août 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11 août 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10 août 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7 août 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6 août 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5 août 2026, 23:02 UTC

News

Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4 août 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3 août 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31 juil. 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30 juil. 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29 juil. 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28 juil. 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27 juil. 2026, 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24 juil. 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

21 juil. 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

20 juil. 2026, 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Comparaison

Variation de prix

Arcutis Biotherapeutics Inc prévision

Objectif de Prix

By TipRanks

47.58% hausse

Prévisions sur 12 Mois

Moyen 36.57 USD 47.58%

Haut 40 USD

Bas 34 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

167 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.